Long-term Effects of Androgen Deprivation in a Patient with Spinal and Bulbar Muscular Atrophy - A Case Report with 14 Years of Follow-up
-
- Hijikata Yasuhiro
- Department of Neurology, Nagoya University Graduate School of Medicine, Japan
-
- Hashizume Atsushi
- Department of Neurology, Nagoya University Graduate School of Medicine, Japan
-
- Yamada Shinichiro
- Department of Neurology, Nagoya University Graduate School of Medicine, Japan
-
- Ito Daisuke
- Department of Neurology, Nagoya University Graduate School of Medicine, Japan
-
- Banno Haruhiko
- Department of Neurology, Nagoya University Graduate School of Medicine, Japan
-
- Suzuki Keisuke
- Department of Neurology, Nagoya University Graduate School of Medicine, Japan Innovation Center for Clinical Research, National Center for Geriatrics and Gerontology, Japan
-
- Sobue Gen
- Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Japan
-
- Katsuno Masahisa
- Department of Neurology, Nagoya University Graduate School of Medicine, Japan
Abstract
<p>Spinal and bulbar muscular atrophy (SBMA) is a progressive hereditary neuromuscular disease caused by the testosterone-dependent accumulation of pathogenic polyglutamine-expanded androgen receptor protein. A 41-year-old man with SBMA received the androgen deprivation agent leuprorelin acetate for 7 years in clinical trials and underwent castration following the trial. Suppression of testosterone levels for 14 years resulted in a slower disease progression, as measured prospectively with quantitative measurements, than the historical control data reported in previous studies. This suggests that long-term androgen deprivation delays disease progression in SBMA. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 58 (15), 2231-2234, 2019-08-01
The Japanese Society of Internal Medicine
